MCID: BCT022
MIFTS: 56

Bacterial Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Bacterial Infectious Disease

MalaCards integrated aliases for Bacterial Infectious Disease:

Name: Bacterial Infectious Disease 12 15
Bacterial Infections 44

Classifications:



External Ids:

Disease Ontology 12 DOID:104
MeSH 44 D001424
NCIt 50 C2890
SNOMED-CT 67 87628006
ICD10 32 A49 A49.9
UMLS 71 C0004623

Summaries for Bacterial Infectious Disease

Disease Ontology : 12 A disease by infectious agent that results in infection, has material basis in Bacteria.

MalaCards based summary : Bacterial Infectious Disease, also known as bacterial infections, is related to opportunistic bacterial infectious disease and commensal bacterial infectious disease. An important gene associated with Bacterial Infectious Disease is CRP (C-Reactive Protein), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Fosfomycin and Nitrofurantoin have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Bacterial Infectious Disease

Diseases related to Bacterial Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1165)
# Related Disease Score Top Affiliating Genes
1 opportunistic bacterial infectious disease 33.3 TNF IFNG CRP
2 commensal bacterial infectious disease 33.1 TNF TLR4 TLR2 MYD88 IL6 IL1B
3 primary bacterial infectious disease 33.0 TNF TLR4 TLR2 NOD2 MYD88 IL6
4 leukocyte adhesion deficiency, type i 32.6 IL17A CXCL8 CSF3 CCR6
5 syphilis 32.5 IL17A CRP CCR6
6 nocardiosis 32.5 TNF IFNG CRP
7 spotted fever 32.5 TNF IL10 IFNG
8 actinomycosis 32.5 TNF IL6 IL1B IL10 CRP
9 campylobacteriosis 32.5 TLR4 IL1B IL10 IFNG
10 paratyphoid fever 32.5 TNF IL1B IFNG CRP CCR6
11 trachoma 32.5 TNF IL6 IL17A IL10
12 pasteurellosis 32.5 TNF ELANE CXCL8
13 neutropenia 32.5 TNF TLR4 IL6 IL1B IL10 IFNG
14 severe congenital neutropenia 32.5 TNF IL1B ELANE CXCL8 CSF3 CAMP
15 macs syndrome 32.5 TNF IL10 IFNG
16 lyme disease 32.5 TNF TLR2 IL6 IL1B IL17A CRP
17 tetanus 32.5 TNF IL6 IL1B IL10 IFNG CRP
18 legionellosis 32.4 TNF TLR4 TLR2 MYD88 IL6 IL1B
19 typhoid fever 32.4 TNF TLR4 IL6 IL1B IFNG CRP
20 plague 32.4 TNF TLR4 TLR2 MYD88 IL6 IL1B
21 common variable immunodeficiency 32.4 TNF TLR2 NOD2 IL6 IL1B IL10
22 leptospirosis 32.4 TNF TLR2 IL6 IL1B IL10 IFNG
23 tularemia 32.4 TNF TLR4 TLR2 MYD88 IL1B IL17A
24 brucellosis 32.4 TNF TLR4 IL6 IL17A IL10 IFNG
25 listeriosis 32.4 TNF TLR2 MYD88 IL6 IL1B IL10
26 toxic shock syndrome 32.4 TNF TLR4 TLR2 IL6 IL1B IL10
27 melioidosis 32.4 TNF TLR4 TLR2 NOD2 IL6 IL10
28 pertussis 32.4 TNF TLR4 MYD88 IRAK4 IL6 IL1B
29 cholera 32.4 TNF IL6 IL1B IL10
30 shigellosis 32.4 TNF TLR4 NOD1 MYD88 IL1B IL10
31 epidemic typhus 32.4 TNF IL10 CRP
32 q fever 32.4 TNF TLR4 TLR2 NOD2 MYD88 IL6
33 tonsillitis 32.4 TNF TLR4 TLR2 IL6 IL1B IL10
34 bacterial sepsis 32.4 TNF TLR4 TLR2 IL6 IL1B IL10
35 blepharitis 32.4 TNF CXCL8 CCR6
36 sickle cell anemia 32.3 TNF IL6 IL1B IL10 CXCL8 CSF3
37 chlamydia 32.3 TNF TLR4 TLR2 NOD1 IL6 IL1B
38 mycobacterium tuberculosis 1 32.3 TNF TLR4 TLR2 NOD2 MYD88 IL17A
39 chronic granulomatous disease 32.3 TNF IL1B IL17A IFNG ELANE CXCL8
40 acute proliferative glomerulonephritis 32.3 TNF IL17A CRP CCR6
41 leprosy 3 32.3 TNF TLR4 TLR2 NOD2 NOD1 IL6
42 filarial elephantiasis 32.3 TLR4 TLR2 IL10
43 acute disseminated encephalomyelitis 32.3 IL1B IL10 CSF3 CCR6
44 pyoderma gangrenosum 32.3 TNF NOD2 CXCL8 CSF3 CCR6
45 whim syndrome 32.2 ELANE CSF3 CCR6
46 cystic fibrosis 32.2 TNF TLR4 TLR2 IL6 IL1B IL17A
47 salmonellosis 32.2 TNF TLR4 TLR2 NOD2 NOD1 MYD88
48 hyper ige syndrome 32.2 TNF TLR4 TLR2 IRAK4 IL6 IL17A
49 acute cystitis 32.1 TNF TLR4 IL6 IL1B IL10 CXCL8
50 haemophilus influenzae 32.0 TNF TLR2 CXCL8

Graphical network of the top 20 diseases related to Bacterial Infectious Disease:



Diseases related to Bacterial Infectious Disease

Symptoms & Phenotypes for Bacterial Infectious Disease

GenomeRNAi Phenotypes related to Bacterial Infectious Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.5 CXCL8 IL10 IL17A IL1B MYD88 NOD1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.5 CXCL8 IL10 IL17A IL1B MYD88 NOD1

MGI Mouse Phenotypes related to Bacterial Infectious Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CAMP CCR6 CSF3 ELANE IFNG IL10
2 immune system MP:0005387 10.25 CAMP CCR6 CRP CSF3 ELANE IFNG
3 homeostasis/metabolism MP:0005376 10.21 CCR6 CRP ELANE IFNG IL10 IL17A
4 digestive/alimentary MP:0005381 10.09 IFNG IL10 IL17A IL6 MYD88 NOD2
5 integument MP:0010771 9.96 CSF3 ELANE IFNG IL10 IL17A IL1B
6 neoplasm MP:0002006 9.81 ELANE IFNG IL10 IL1B IL6 MYD88
7 respiratory system MP:0005388 9.56 IFNG IL10 IL17A IL6 MYD88 TLR2
8 skeleton MP:0005390 9.32 IFNG IL10 IL17A IL1B IL6 MYD88

Drugs & Therapeutics for Bacterial Infectious Disease

Drugs for Bacterial Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 410)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fosfomycin Approved Phase 4 23155-02-4 446987
2
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
3
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
4
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
5
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Cefdinir Approved Phase 4 91832-40-5 6915944
8
Sulfamethoxazole Approved Phase 4 723-46-6 5329
9
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
10
Simethicone Approved Phase 4 8050-81-5
11
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
12
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
13
Iodine Approved, Investigational Phase 4 7553-56-2 807
14
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
15
carbamide peroxide Approved Phase 4 124-43-6
16
Sulbactam Approved Phase 4 68373-14-8
17
Retapamulin Approved Phase 4 224452-66-8 6918462
18
Ethanol Approved Phase 4 64-17-5 702
19
Ibuprofen Approved Phase 4 15687-27-1 3672
20
Povidone-iodine Approved Phase 4 25655-41-8
21
Povidone Approved Phase 4 9003-39-8 131751496
22
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
23
Promethazine Approved, Investigational Phase 4 60-87-7 4927
24
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
25
Telavancin Approved Phase 4 372151-71-8
26
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
27
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
28
Acetaminophen Approved Phase 4 103-90-2 1983
29
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
30
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
33
Metronidazole Approved Phase 4 443-48-1 4173
34
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
35
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
36
Ephedrine Approved Phase 4 299-42-3 9294
37
Phenylephrine Approved Phase 4 59-42-7 6041
38
Pseudoephedrine Approved Phase 4 90-82-4 7028
39
Clarithromycin Approved Phase 4 81103-11-9 84029
40
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
41
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
42
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
43
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
44
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
45
Cefazolin Approved Phase 4 25953-19-9 656510 33255
46
Vancomycin Approved Phase 4 1404-90-6 441141 14969
47
Piperacillin Approved Phase 4 66258-76-2 43672
48
Tazobactam Approved Phase 4 89786-04-9 123630
49
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
50
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919

Interventional clinical trials:

(show top 50) (show all 535)
# Name Status NCT ID Phase Drugs
1 Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients Unknown status NCT02117986 Phase 4 colistin
2 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
3 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
4 An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections Unknown status NCT01297842 Phase 4 Ertapenem;Meropenem or Imipenem
5 Increased Second-line Eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Conventional Triple Therapy. Unknown status NCT01572597 Phase 4 10RAC+acetylcystein;10RAC+metronidazole
6 Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection Unknown status NCT01966653 Phase 4 nitrofurantoin;fosfomycin
7 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
8 An Open Observational Study For The Rabeprazole Administration In Adult Subjects With Helicobacter Pylori (H. Pylori) Infection Completed NCT00216450 Phase 4 rabeprazole sodium
9 A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP) Completed NCT02891915 Phase 4 Amoxicillin;Amoxicillin-clavulanate;Cefdinir
10 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
11 Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections Completed NCT00147511 Phase 4 linezolid
12 Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem Completed NCT01732250 Phase 4 Colistin;Meropenem
13 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
14 Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections Completed NCT03397914 Phase 4 Colistimethate Sodium
15 A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis? Completed NCT02285075 Phase 4 temocillin PK/PD in haemodialysis
16 A Double Blinded Randomized Controlled Trial for the Management of Pediatric Community Acquired Skin Abscesses - To Treat or Not to Treat With Antibiotics Completed NCT00679302 Phase 4 Trimethoprim-sulfamethoxazole;Placebo group
17 A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery Completed NCT00575380 Phase 4 AzaSite Eye Drops;Vigamox Eye Drops
18 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration Completed NCT00575367 Phase 4 AzaSite (azithromycin ophthalmic solution);Vigamox (moxifloxacin hydrochloride ophthalmic solution)
19 A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration Completed NCT00564447 Phase 4 Azithromycin;Moxifloxacin
20 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
21 Randomized, Multi-Center, Comparative Trial of Short-Course Empiric Antibiotic Therapy Versus Standard Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the Intensive Care Unit (ICU) Completed NCT00410527 Phase 4 Merrem
22 Randomized, Open-label, Comparative Study of Zosyn (Pip/Tazo [12g/1.5g]) Administered by Daily 24hr Continuous Infusion vs Zosyn (Pip/Tazo) [3g/0.375g]) q6h for the Treatment of Hospitalized Patients With Complicated Intra-abdominal Infection Completed NCT00044928 Phase 4 Piperacillin/Tazobactam
23 Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria Completed NCT00478855 Phase 4 Tazocin (Piperacillin/Tazobactem)
24 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections Completed NCT03233438 Phase 4 Dalbavancin;Usual Care
25 Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria Completed NCT00488189 Phase 4 Tazocin (pipercillin/tazobactam)
26 A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection Completed NCT02092506 Phase 4 10 day triple therapy;10 day sequential therapy;10 day concomitant therapy
27 Association of Antibiotic Utilization Measures and Control of Extended-spectrum-lactamases (ESBLs) Completed NCT00254696 Phase 4 Extended-Spectrum-Lactamases (ESBLs)
28 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal
29 A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms Completed NCT01623154 Phase 4
30 A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN) Completed NCT03369951 Phase 4 Minocycline
31 An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects Completed NCT00939562 Phase 4 doxycycline monohydrate tablet;doxycycline carragenate tablet
32 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
33 Efficacy and Safety of CRO-SBT Performed in Children With Acute Bacterial Infection Completed NCT04066621 Phase 4 Ceftriaxone Sodium and Sulbactam Sodium for Injection
34 Comparison of Amukin Versus Biseptine Use for Dressing Application of Epicutaneocavous Catheters for Nosocomial Infection Prevention Completed NCT00389558 Phase 4
35 Steroids for Corneal Ulcers Trial Completed NCT00324168 Phase 4 Antibiotics;Topical corticosteroid;Placebo
36 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
37 Leukocyte Depletion of Autologous Whole Blood: Impact on Perioperative Infection Rate and Length of Hospital Stay for Hip Arthroplasty Patients Completed NCT00176124 Phase 4
38 An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months Completed NCT00555061 Phase 4 Retapamulin Ointment, 1%
39 Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics Completed NCT02079298 Phase 4 Treatment with fluconazole.;2. Treatment with both fluconazole and Ibuprofen.;3. Treatment with ibuprofen.
40 Skin Disinfection With Octenidine Dihydrochloride for the Prevention of Catheter-Associated Infections - A Double-Blind, Randomized, Controlled Trial Completed NCT00515151 Phase 4 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol;74% Ethanol with 10% 2-propanol
41 A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections Completed NCT00965848 Phase 4 Doripenem
42 A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483) Completed NCT02339155 Phase 4 Diphenhydramine
43 A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load Completed NCT03133312 Phase 4 Chlorhexidine Gluconate;Povidone-Iodine Scrub and Paint
44 An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana Completed NCT00493922 Phase 4
45 An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 3 Months to 17 Years Recruiting NCT02013141 Phase 4 Telavancin
46 A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression Recruiting NCT02719392 Phase 4 Minocycline
47 Intravenous to Oral Antibiotic Switch Therapy for Probable Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness Recruiting NCT03247920 Phase 4 Amoxicillin Clavulanate;Antibiotics
48 Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection Recruiting NCT02572791 Phase 4 Chlorhexidine;Mupirocin
49 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
50 Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial Recruiting NCT03671967 Phase 4 Piperacillin/tazobactam;Meropenem

Search NIH Clinical Center for Bacterial Infectious Disease

Cochrane evidence based reviews: bacterial infections

Genetic Tests for Bacterial Infectious Disease

Anatomical Context for Bacterial Infectious Disease

MalaCards organs/tissues related to Bacterial Infectious Disease:

40
Skin, Neutrophil, Kidney, T Cells, Bone Marrow, Monocytes, Liver

Publications for Bacterial Infectious Disease

Articles related to Bacterial Infectious Disease:

(show top 50) (show all 23603)
# Title Authors PMID Year
1
CCL22 is involved in the recruitment of CD4+CD25 high T cells into tuberculous pleural effusions. 54 61
20337996 2010
2
How to use: C-reactive protein. 61 54
20351152 2010
3
[HBD-1 and hBD-2 are expressed in cervico-vaginal lavage in female genital tract due to microbial infections]. 54 61
20476598 2010
4
Predicting severe bacterial infections in well-appearing febrile neonates: laboratory markers accuracy and duration of fever. 61 54
19949364 2010
5
High-throughput and single-cell imaging of NF-kappaB oscillations using monoclonal cell lines. 61 54
20233427 2010
6
Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. 61 54
20171921 2010
7
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 61 54
20192933 2010
8
The role of Toll-like receptor signaling in human immunodeficiencies. 54 61
19430930 2010
9
rBPI(21) promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes. 54 61
20027298 2009
10
Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. 61 54
19238436 2009
11
Phenylbutyrate induces antimicrobial peptide expression. 54 61
19770273 2009
12
Hypoxia-altered signaling pathways of toll-like receptor 4 (TLR4) in human corneal epithelial cells. 54 61
19960069 2009
13
C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. 54 61
19664100 2009
14
The potential role of C-reactive protein in distinguishing cytomegalovirus from tuberculosis and bacterial infections in renal transplant recipients. 61 54
19594772 2009
15
Clinical significance of complement deficiencies. 54 61
19758139 2009
16
Application of ultralow doses of antibodies to interferon-gamma in complex therapy of bacterial infections and prophylaxis of bacterial complications. 61 54
20027351 2009
17
The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection. 54 61
19675669 2009
18
Intracellular receptor for human host defense peptide LL-37 in monocytes. 61 54
19605696 2009
19
TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. 54 61
19596984 2009
20
Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin. 54 61
19158133 2009
21
Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. 54 61
19479878 2009
22
Diagnostic potential of urinary tumor necrosis factor-alpha in children with acute pyelonephritis. 54 61
19395784 2009
23
Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. 54 61
19365169 2009
24
IL-17 and anti-bacterial immunity: protection versus tissue damage. 54 61
19283706 2009
25
A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. 54 61
19067670 2009
26
Concentration dependent aggregation properties of chlorhexidine salts. 54 61
18926892 2009
27
The role of infection in the development of non-valvular atrial fibrillation: up-regulation of Toll-like receptor 2 expression levels on monocytes. 61 54
19167648 2009
28
Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. 54 61
19436694 2009
29
Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. 54 61
19728551 2009
30
IRAK-4 inhibitors for inflammation. 61 54
19689377 2009
31
Selective excretion of anti-inflammatory cytokine interleukin-10 in a superantigen-inducing neonatal infectious disease. 54 61
19084429 2009
32
C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. 61 54
19351421 2009
33
[Evaluation of inflammatory and renal injury markers in youngest children with pyelonephritis]. 61 54
19205372 2008
34
Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. 61 54
18986247 2008
35
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase. 61 54
19067895 2008
36
Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. 54 61
18534215 2008
37
An investigation of the C4 gene arrangement in ethnic Chinese (Taiwanese). 61 54
18680512 2008
38
C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis. 61 54
18581011 2008
39
Functional activity of MD-2 polymorphic variant is significantly different in soluble and TLR4-bound forms: decreased endotoxin binding by G56R MD-2 and its rescue by TLR4 ectodomain. 61 54
18424732 2008
40
Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. 54 61
18240280 2008
41
Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. 61 54
18202345 2008
42
Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells. 61 54
18380907 2008
43
Stimulus-dependent impairment of the neutrophil oxidative burst response in lactoferrin-deficient mice. 61 54
18321995 2008
44
Interleukin-6 concentrations in wound fluids rather than serological markers are useful in assessing bacterial triggers of ulcer inflammation. 61 54
18179556 2008
45
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. 61 54
18200634 2008
46
Staphylococcal pericarditis, and liver and paratracheal abscesses as presentations in two new cases of interleukin-1 receptor associated kinase 4 deficiency. 61 54
18174872 2008
47
[Immune-mediated inflammatory diseases and psoriasis]. 54 61
18466796 2008
48
Variable responses of formyl peptide receptor haplotypes toward bacterial peptides. 54 61
18253729 2008
49
Neutrophil function and molecular analysis in severe leukocyte adhesion deficiency type I without separation delay of the umbilical cord. 54 61
17651379 2008
50
Formyl peptide receptor-mediated ERK1/2 activation occurs through G(i) and is not dependent on beta-arrestin1/2. 54 61
18060741 2008